The upcoming Biotech Act offers an opportunity to enhance Europes position as a global leader in biotechnology. To remain at the forefront of scientific breakthroughs, the EU must adopt policies that address the challenges and leverage the opportunities in the biotech space.
Pfizer
Company · United States · EU Transparency Register 4263301811-33
Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 925 companies & groups on this site, they rank #805 by legislative files engaged — a count of participation, not a measure of influence.
Declares membership of
- In 2025 Pfizer was a member of: EFPIA
- Vaccines Europe →
- EuropaBio →
- Amcham EU
- BusinessEurope →
- European Policy Centre →
- European Business Summits
- Friends of Europe.
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026).
- Register category
- Companies & groups
- Registered as
- Pfizer Inc. (PFE)
- Head office
- New York, United states
- EU office
- Brussels
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Pfizer in PolicySpeak: request access →
Work at Pfizer? so we know who speaks for it.
Their record over time
Pfizer filed 1 position on 11 Jun 2025, across 1 of the 326 legislative files tracked here, attaching a full position paper 1 time.
What they argued
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Is this your organization?
Everything on this page comes from Pfizer’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.